ReviewEuropean radiology2026
ESR Essentials: uterine cancers-practice recommendations by the European Society of Urogenital Radiology.
Review in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine cancers include endometrial cancer (EC), cervical cancer (CC), and uterine sarcomas, with leiomyosarcoma being the most common subtype. Each tumour type has distinct biological behaviour, imaging features, and treatment approaches. Radiologists must be familiar with normal uterine anatomy and its variations, as well as key imaging characteristics and common patterns of tumour spread to ensure accurate staging and optimal treatment selection. MRI is the imaging modality of choice for evaluating uterine malignancies due to its excellent soft tissue contrast and multiplanar capabilities. Accurate assessment requires dedicated multiparametric protocols, as recommended by the European Society of Urogenital Radiology (ESUR), including high-resolution T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) sequences when appropriate. 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) complements MRI in patients with CC by providing the highest accuracy for detecting lymph-node and distant metastases. CT is mainly used for systemic evaluation. This article presents a practical guide for radiologists, describing the main clinical indications, patient preparation, and tailored MRI protocols. It also highlights key imaging findings that should be evaluated and reported. KEY POINTS: MRI is the preferred imaging modality for evaluating uterine malignancies due to its superior soft tissue contrast and multiplanar capabilities. Common clinical indications include MRI staging of endometrial and cervical cancers, assessment of eligibility for fertility preservation, and characterisation of indeterminate myometrial lesions. Adherence to established imaging guidelines is strongly recommended to ensure high-quality images as well as complete and clinically relevant radiology reports.
Indexed as
Identifiers
42380325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.